+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim

Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim

Drugs 62 Suppl 1: 33-46

Non-Hodgkin's lymphoma (NHL) is one of the ten most common cancers in the developed world. The incidence has increased significantly over the past two decades and it is a particular burden in patients over the age of 60 years. The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Haematological growth factors, such as granulocyte colony-stimulating factor (G-CSF), can be used to ameliorate chemotherapy-induced neutropenia, thus facilitating delivery of chemotherapy at the planned dose intensity. The International Prognostic Index is able to identify high-risk patients who are unlikely to be cured with standard primary chemotherapy. In these patients, the use of dose-intensive therapy, including high-dose chemotherapy with stem cell support, is being evaluated as potential primary therapy. Stem cell transplantation is currently the treatment of choice for patients with relapsed NHL or those with chemosensitive refractory disease. Autologous peripheral blood stem cells mobilised into the circulation by G-CSF help achieve rapid haematological reconstitution and are now the preferred source of stem cells over bone marrow for this form of therapy. G-CSF is also used to support allogeneic transplantation, which exerts a therapeutic graft-versus-lymphoma effect. Administration of G-CSF following autologous or allogeneic peripheral blood stem cell transplantation accelerates neutrophil recovery.

(PDF same-day service: $19.90)

Accession: 035980890

Download citation: RISBibTeXText

PMID: 12479593

DOI: 10.2165/00003495-200262001-00003

Related references

Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: Evaluation of the role of G-CSF; Quality-of-life analysis and long-term follow-up. American Journal of Hematology 66(3): 178-188, 2001

Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma. American Journal of Hematology 84(7): 457-459, 2009

Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. Leukemia & Lymphoma 44(2): 349-351, 2003

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clinical Oncology ) 10(2): 107-114, 1998

Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. A report from the Italian Lymphoma Study Group (GISL). American Journal of Clinical Oncology 18(1): 8-14, 1995

Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group. Annals of Oncology 9(6): 633-638, 1998

Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal of Clinical Oncology 6(12): 1832-1837, 1988

Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG). Haematologica 76(6): 485-490, 1991

Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen. Hematological Oncology 9(4-5): 253-257, 1991

Studies on the treatment and management of malignant lymphoma part 2. combination chemotherapy for diffuse large cell non hodgkin's lymphoma superiority of adriamycin combination. Okayama Igakkai Zasshi 100(5-6): 621-632, 1988

Oral combination chemotherapy in conjunction with filgrastim in the treatment of AIDS-related non-Hodgkins lymphoma. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 14(4): A37, 1997

Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Japanese Journal of Clinical Hematology 35(7): 635-641, 1994

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 19(2): 389-397, 2001

Ancestim in combination with filgrastim can mobilize sufficient peripheral blood progenitor cells to support high-dose salvage chemotherapy and late intensification in relapsing and refractory aggressive non-Hodgkins lymphoma A GELA Study. Blood 102(11): 415b, November 16, 2003